doi: 94
Who is eligible to use Semaglutide for weight loss
The trend toward prolonged pregnancy and reduced neonatal morbidity would require confirmation in larger trials
duy tr ln da trng sng v khe mnh, bn nn s dng sn phm theo ng liu trnh v kt hp vi cc bin php chm sc da khc
CONTRAINDICATIONS History of hypersensitivity reaction to tirzepatide or any of its excipients Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) PRECAUTIONS Kidney disease No dose adjustment is recommended in patients with any degree of renal impairment Liver disease No dose adjustment is recommended in patients with any degree of liver disease Stomach disorders Tirzepatide slows gastric emptying and is not recommended in patients with significant stomach disorders, including diabetic gastroparesis General anesthesia or deep sedation GLP-1 therapies, like tirzepatide, slow gastric emptying, possibly increasing the risk of residual gastric contents and pulmonary aspiration in patients receiving anesthesia or deep sedation for procedures
A randomized, double-blind, multicenter trial in HIV patients with non-alcoholic fatty liver disease (NAFLD) found that tesamorelin, dosed at 2 mg daily for twelve months, reduced liver fat and prevented fibrosis progression, while also decreasing hepatic inflammatory gene expression and increasing markers of oxidative phosphorylation findings some researchers have suggested point toward a direct hepatoprotective mechanism that goes beyond simple fat reduction, though this remains an active area of investigation rather than a settled conclusion
